

1. Muir C. Cancer of unknown primary site. *Cancer* 1995;75:353–356.
2. Pavlidis N, Briassoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. *Eur J Cancer* 2003;39:1990–2005.
3. Nystrom JS, Werner JM, Heffelfinger-Juttner J, et al. Metastatic and histologic presentations in unknown primary cancer. *Semin Oncol* 1977;4:53–58.
4. Gatter KC, Alcock C, Heryet A, et al. Clinical importance of analysing malignant tumors of uncertain origin with immunohistochemical techniques. *Lancet* 1985;2:1302–1305.
5. Horning SJ, Carrier EK, Rouse RV, et al. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment. *J Clin Oncol* 1989;7:1281–1287.
6. Pentheroudakis G, Goulinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. *Eur J Cancer* 2007;43:2026–2036.
7. Owen KA. Pathologic evaluation of unknown primary cancer. *Semin Oncol* 2009;36:8–37.
8. Hainsworth JD, Wright EP, Gray GF Jr, Greco FA. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. *J Clin Oncol* 1987;5:1272.
9. Dennis JL, Oien KA. Hunting the primary: novel strategies for defining the origin of tumours. *J Pathol* 2005;205:236–247.
10. Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. *Ann Oncol* 2012;23:271–277.
11. Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. *Cancer Treat Rev* 2011;37:358–365.
12. Kerr SE, Schnabel CA, Sullivan PS, et al. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors. *Modern Pathology* 2014;27:44–54.
13. Woltering E, Anthony LB, Diebold AE, et al. Gene expression profiling to predict site of metastatic neuroendocrine tumors presenting with an unknown primary. *J Clin Oncol* 2013 (suppl: abstract 4141).
14. Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. *N Engl J Med* 1983;109:1275–1281.
15. Battifora H, Trowbridge IS. A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms. *Cancer* 1983;51:816–821.
16. Mackey B, Ordonez NG. Pathological evaluation of neoplasms with unknown primary tumor site. *Semin Oncol* 1993;20:206–228.
17. Liu H, Shi H, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues. *Am J Clin Pathol* 2012;138:57–64.
18. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors; a study of 1840 cases. *Am J Surg Pathol* 2009;33:1401–1408.
19. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinoma. *Appl Immunohistochem* 1995;3:99–107.
20. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. *Eur J Cancer* 2002;38:758–763.
21. Cheney L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. *Cancer* 2004;101:2006–2010.
22. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. *Appl Immunohistochem Mol Morphol* 2010;18:3–8.
23. Arnold A, Cossman J, Bakshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. *N Engl J Med* 1983;309:1593–1599.
24. Rowley JD. Recurring chromosome abnormalities in leukemia and lymphoma. *Semin Hematol* 1990;27:122–136.
25. Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenetic studies in the diagnosis of patients with midline carcinomas of unknown primary site. *J Clin Oncol* 1995;13:274–282.
26. Turc-Carel C, Philip I, Berger MP, et al. Chromosomal translocation in Ewing's sarcoma. *N Engl J Med* 1983;309:497–498.
27. Whang-Peng J, Triche TJ, Knutsen T, et al. Chromosome translocation in peripheral neuroepithelioma. *N Engl J Med* 1984;311:584–585.
28. Gerald WL, Ladanyi M, de Alava E, et al. Clinical, pathologic and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumors and its variants. *J Clin Oncol* 1998;16:3028–3036.
29. French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. *J Clin Oncol* 2004;22:4135–4139.
30. Atkin NB, Baker MC. Specific chromosome change, i(12p), in testicular tumors. *Lancet* 1982;2:1349.
31. Ilson DH, Motzer RJ, Rodriguez E, et al. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. *Semin Oncol* 1993;20:229–237.
32. Summersill B, Coker H, Osin P, et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. *Diagn Mol Pathol* 1998;7:260–266.
33. Yuge NK, Mochiki M, Nibu K, et al. Detection of Epstein-Barr virus in metastatic lymph nodes of patients with nasopharyngeal carcinoma and a primary unknown cancer. *Arch Otolaryngol Head Neck Surg* 2003;129:338–340.
34. Feinmesser R, Miyazaki I, Chenn R, et al. Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. *N Engl J Med* 1992;326:17–21.
35. Lipshultz RJ, Morris D, Chee M, et al. Using oligonucleotide probe arrays to access genetic diversity. *Biotechniques* 1995;19:442–447.
36. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. *Science* 1995;270:467–470.
37. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science* 1999;286:531–537.
38. Greco FA, Erlander MG. Molecular classification of unknown primary cancer site. *Mol Diagn Ther* 2009;13:367–373.
39. Li X, Quigg RJ, Zhou J, et al. Clinical utility of microarrays: current status, existing challenges and future outlook. *Curr Genomics* 2008;9:466–474.
40. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? *Nature Rev Cancer* 2007;7:545–553.
41. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. *Proc Natl Acad Sci U S A* 2001;98:15149–15154.
42. MacConaill LE. Existing and emerging technologies for genomic profiling. *J Clin Oncol* 2013;31:1815–1824.
43. Abaan OD, Polley EC, Davis SR, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. *Cancer Res* 2013;73:4372–4382.
44. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. *Cancer Res* 2001;61:7388–7393.
45. Bloom G, Yang IV, Boulware D, et al. Multi-platform, multi-site, microarray-based human tumor classification. *Am J Path* 2004;164:9–16.
46. Tothill RW, Kowalczyk A, Rischin D, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. *Cancer Res* 2005;65:4031–4040.
47. Talantov D, Baden J, Jatko T. A quantitative reverse transcriptase-polymerase chain reaction array to identify metastatic carcinoma tissue of origin. *J Mol Diagn* 2006;8:320.
48. Rosenfeld N, Aharonov R, Meiril E, et al. MicroRNAs accurately identify cancer tissue origin. *Nature Biotech* 2008;26:462–469.
49. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. *J Clin Oncol* 2009;27:2503–2508.
50. Ma X-J, Pate R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction array. *Arch Path Lab Med* 2006;130:465–473.
51. Pillai R, Deeter R, Rigl CT, et al. Validation of a microarray-based gene expression test for tumors with uncertain origins using formalin-fixed paraffin-embedded (FFPE) specimens. *J Mol Diagn* 2011;13:48–56.
52. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. *Cancer Treat Rev* 2009;35:221–227.
53. Varadhachary G, Talantov D, Raber M, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. *J Clin Oncol* 2008;26:4442–4448.
54. Bridgewater J, van Laar R, Floore A, et al. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. *Br J Cancer* 2008;98:1425–1430.
55. Horlings HM, van Laar R, Kerst J-M, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. *J Clin Oncol* 2008;26:4435–4441.
56. van Laar RK, Ma XJ, de Jong D, et al. Implementation of a novel microarray-based diagnostic test for cancer of known primary. *Int J Cancer* 2009;125:1390–1397.
57. Monzon FA, Medeiros F, Lyons-Weiler M, Henner WD. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. *Diagn Pathol* 2010;5:3.
58. Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: tissue of origin prediction. *Oncologist* 2010;15:500–506.
59. Erlander MG, Ma XJ, Kesty NC, et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. *J Mol Diagn* 2011;13:493–503.
60. Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. *Clin Cancer Res* 2012;18:3952–3960.
61. Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. *The Oncologist* 2012;17:801–812.
62. Weiss LM, Cha PG, Schroeder BE, et al. Blinded comparator study of immunohistochemistry analysis versus 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. *J Molecular Diagn*. 2013;15:263–269.

63. Handorf CR, Kulkarni A, Grenut JD, et al. A multisite study directly comparing the diagnostic accuracy of the gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. *Am J Surg Pathol* 2013;37:1067–1075.
64. Gross-Goupil M, Massard C, Lesimple T, et al. Identifying the primary site using gene expression profiling in patients with carcinoma of unknown primary; a feasibility study from the GEFCAPI. *Onkologie* 2011;35:54–55.
65. Pentheroudakis G, Pavlidis N, Fountzilias G, et al. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. *Molecular Cancer* 2013; 12:57.
66. Nystrom SJ, Homberger JC, Varadhachary GR, et al. Clinical utility of gene-expression profiling for tissue-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment and survival. *Oncotarget* 2012;3:620–628.
67. Varadhachary Gr, Spector Y, Abbruzzese JL, et al. Propective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. *Clin Cancer Res* 2011;17:4063–4070.
68. Ferracin M, Pedriali M, Veronese A, et al. Micro RNA profiling for the identification of cancers with unknown primary tissue of origin. *J Pathol* 2011;225:43–53.
69. Greco FA, Lennington WJ, Spigel DR, et al. Molecular profiling diagnosis in unknown primary cancer; accuracy and ability to complement standard pathology. *J Natl Cancer Inst* 2013;105:782–790.
70. Morawietz L, Floore A, Stork-Sloats L, et al. Comparison of histopathological and gene expression-based typing of cancer on unknown primary. *Virchows Arch* 2010; 456:23–29.
71. Greco FA, Spigel DR, Hainsworth JD. Molecular tumor profiling of poorly differentiated neoplasms of unknown primary site. *J Clin Oncol* 2013;31: 217–223.
72. Sorscher SM, Greco FA. Papillary renal carcinoma presenting as a cancer of unknown primary and diagnosed through gene expression profiling. *Case Rep Oncol* 2012;5:229–232.
73. Choi YR, Han HS, Lee OJ, et al. Metastatic renal cell carcinoma in a supraclavicular lymph node with no known primary; a case report. *Cancer Res Treat* 2012; 44:215–218.
74. Hainsworth JD, Spigel DR, Greco FA. Renal cell carcinoma presenting as cancer of unknown primary: diagnosis by molecular tumor profiling. *J Clin Oncol* 2013;31:abstract e15501.
75. Seve P, Billotey C, Broussulle C, et al. The role of 2-deoxy-2-[F-18] fluorodeoxyglucose positron emission tomography in disseminated carcinoma of unknown primary site. *Cancer* 2007;109:292–299.
76. Moller AK, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical cancer of unknown primary site. *Oncologist* 2012;17:1146–1154.
77. Welborn J, Jenks H, Taplett J, et al. High-grade neuroendocrine carcinomas display unique cytogenetic aberrations. *Cancer Genet Cytogenet* 2004;155:33–41.
78. Swarts DR, Ramackers FC, Speel EJ, et al. Molecular and cellular biology of neuroendocrine tumors: evidence for separate biological entities. *Biochim Biophys Acta* 2012;1826:255–271.
79. Moertel CG, Kovals LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer* 1991;68:227–232.
80. van der Gaast A, Verwey J, Prins E, Splinter TAW. Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinoma. *Cancer* 1990;65:422–424.
81. Kasimis BS, Wuerker RB, Malefatto JP, Moran EM. Prolonged survival of patients with extrapulmonary small cell carcinoma arising in the neck. *Med Pediatr Oncol* 1983;11:27–32.
82. Rusthoven KE, Koshy M, Pauline AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. *Cancer* 2004;101:2641–2649.
83. Califano J, Westra WH, Koch W, et al. Unknown primary head and neck squamous carcinoma: molecular identification of the site of origin. *J Natl Cancer Inst* 1999;91:599–604.
84. Jones AS, Cook JA, Phillips DE, et al. Squamous carcinoma presenting as an enlarged cervical lymph node. *Cancer* 1993;72:1756–1761.
85. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. *Cancer* 2004;100:1776–1785.
86. Lapeyre M, Malissard L, Peiffert D, et al. Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary? *Int J Radiat Oncol Biol Phys* 1997;39:291–296.
87. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families. *Lancet* 1982;2:795–797.
88. Schorge JO, Muto MC, Welch WR et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germ-line BRCA1 mutations. *J Natl Cancer Inst* 1998;90:841–845.
89. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to a serous tumor origin? *Am J Surg Pathol* 2009;33:376–383.
90. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. *Mod Pathol* 2009;22:985–988.
91. Ransom DT, Patel SR, Kenney GL, et al. Papillary serous carcinoma of the peritoneum: a review of 33 cases treated with cisplatin-based chemotherapy. *Cancer* 1990;66:1091–1094.
92. Piver MS, Eltabbakh GH, Hempling RE, et al. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin/doxorubicin/cyclophosphamide or paclitaxel/cisplatin. *Gynecol Oncol* 1997;67:141–146.
93. Pentheroudakis G, Pavidis N. Serous papillary peritoneal carcinoma: unknown primary tumor ovarian cancer counterpart or a distinct entity? A systematic review. *Crit Rev Oncol Hematol* 2010;75:27–42.
94. Shah IA, Jayram L, Gani OJ, et al. Papillary serous carcinoma of the peritoneum in a man. *Cancer* 1998;82:860–866.
95. Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. *Breast Cancer Res Treat* 2010;119:1–11.
96. Bhatia SK, Saclarides TJ, Witt TR, et al. Hormone receptor studies in axillary metastases from occult breast cancer. *Cancer* 1987;59:1170–1172.
97. Block EF, Meyer MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. *Am Surg* 1998;64:906–908.
98. Schorn C, Fischer U, Luftner-Nagel S, et al. MRI of the breast in patients with metastatic disease of unknown primary. *Eur Radiol* 1999;9:470–473.
99. Henry-Tillman RS, Fischer U, Luftner-Nagel S, et al. MRI of the breast in patients with metastatic disease of unknown primary. *Eur Radiol* 1999;9:470–473.
100. Ellerbreek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. *Cancer* 1990;66:1461–1467.
101. Tell DT, Khoury JM, Taylor HG, et al. Atypical metastasis from prostate cancer: clinical utility of the immunoperoxidase technique for prostate-specific antigen. *JAMA* 1985;253:3574–3575.
102. Gentile PS, Carloss HW, Huang T-Y, et al. Disseminated prostate carcinoma simulating primary lung cancer. *Cancer* 1988;62:711–715.
103. Richardson RL, Greco FA, Wolff S, et al. Extragonadal germ cell malignancy: value of tumor markers in metastatic carcinoma of young males. *Proc Am Assoc Clin Oncol Am Assoc Clin Res* 1979;20 (abstr 204).
104. Hainsworth JD, Greco FA. Poorly differentiated carcinoma of unknown primary site. In: Fer MF, Greco FA, Oldham R, eds. *Poorly Differentiated Neoplasms and Tumors of Unknown Origin*. Orlando, FL: Grune Stratton; 1986:189.
105. Fox RM, Woods RL, Tattersall MHN. Undifferentiated carcinoma in young men: the atypical teratoma syndrome. *Lancet* 1979;1:1316–1318.
106. Rades D, Kuhnel G, Wildfang I, et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. *Ann Oncol* 2001;12:1605–1609.
107. Nguyen LN, Maor MH, Oswald MJ. Brain metastases as the only manifestation of an undetected primary tumor. *Cancer* 1998;83:2181–2184.
108. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. *Cancer Principles and Practice of Oncology*, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:2363.
109. Fernandez JA, Suanz C, Martinez JA, et al. Metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary tumor: prognostic factors. *Clin Otolaryngol* 1998;23:158–163.
110. De Braud F, Heilbrun LK, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck: advantages of an aggressive treatment. *Cancer* 1989;64:510–515.
111. Guarischi A, Keane TJ, Elkahim T. Metastatic inguinal nodes from an unknown primary neoplasm: a review of 56 cases. *Cancer* 1987;59:572–577.
112. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* 2009; 27:4656.
113. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly recognized clinicopathologic entity. *Ann Intern Med* 1988;109:364–371.
114. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. *J Clin Oncol* 2006;24:3548–3554.
115. Richardson RL, Schoumacher RA, Fer MF, et al. The unrecognized extragonadal germ cell cancer syndrome. *Ann Intern Med* 1981;94:181–186.
116. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. *Ann Intern Med* 1986;104:547–553.
117. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. *N Engl J Med* 1995;329:257–263.
118. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12 year experience at a single institution. *J Clin Oncol* 1992;10:912–922.
119. Falkson CI, Cohen GL. Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. *Oncology* 1998;55:116–121.

120. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary cancer: a phase II Hellenic Cooperative Oncology Group study. *J Clin Oncol* 2000;18:3101–2107.
121. Raber MN, Faintuch J, Abbruzzese J, et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary site. *Ann Oncol* 1991;2:519–520.
122. Pavlidis N, Kosmidis P, Skaros D, et al. Subsets of tumors responsive to cisplatin or combinations in patients with carcinoma of unknown primary site. *Ann Oncol* 1992;3:631–634.
123. van der Gaast A, Verweij J, Henzen-Logmans SC, et al. Carcinoma of unknown primary; identification of a treatable subset. *Ann Oncol* 1990;1:119–122.
124. Briasoulis E, Tsavaris N, Fountzilas G, et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: a Hellenic Cooperative Oncology Group phase II trial. *Oncology* 1998;55:426–430.
125. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008;26:2013–2019.
126. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). *J Clin Oncol* 2008;26:5326–5334.
127. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon cancer-profile changing paradigm and emerging definitions. *Lancet Oncol* 2008;9:596–599.
128. Varadhachary GR, Karanth S, Qiao W, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. *In J Clin Oncol* 2014;19:479–484.
129. Greco FA, Lenington WJ, Spigel DR, et al. Carcinoma of unknown primary site: outcomes in patients with colorectal profile treated with site-specific chemotherapy. *J Cancer Ther* 2012;3:37–43.
130. Hainsworth JD, Schnabel CA, Erlander MG, et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. *Clin Colorectal Cancer* 2012;11:112–118.
131. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. *J Clin Oncol* 2012; 31:217–223.
132. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT, Lawrence TS, Rosenber SA, eds, *Cancer Principles and Practice of Oncology*, 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2011: 2033.
133. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. *Semin Oncol* 2009;36:65–74.
134. Lee J, Hahn S, Kim D-W, et al. Evaluation of survival benefits by platinum and taxanes for unfavorable subset of carcinoma of unknown primary; a systematic review and meta-analysis. *Br J Cancer* 2013;108:39–48.
135. Altman E, Cadman E. An analysis of 1,539 patients with cancer of unknown primary site. *Cancer* 1986;57:120–124.
136. Hess KR, Abbruzzese MC, Lenzi R, et al. Classification and regression free analysis of 1000 consecutive patients with unknown primary carcinoma. *Clin Cancer Res* 1999;5:3403–3410.
137. Holmes FT, Fouts TL. Metastatic cancer of unknown primary site. *Cancer* 1970;26:816–820.
138. Kremenz ET, Cerise EJ, Foster DC, et al. Metastases of undetermined source. *Curr Probl Cancer* 1979;4:4–37.
139. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at the Johns Hopkins Hospital from 1965–1979. *Med Pediatr Oncol* 1982;10:569–574.
140. Moertel CG, Reitmeier RJ, Schutt AJ, et al. Treatment of the patient with adenocarcinoma of unknown primary site. *Cancer* 1972;30:1469–1472.
141. Van de Wouw AJ, Janssen-Heijnen MLC, Coebergh JWW, et al. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands 1984–1992. *Eur J Cancer* 2002;38:409–413.
142. Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumors. *Eur J Cancer* 2002;38:1810–1812.
143. Greco FA. Therapy of adenocarcinoma of unknown primary: are we making progress? *J Natl Compr Conc Netw* 2008;6:1061–1067.
144. Hainsworth JD, Erland JB, Kalman CA, et al. Carcinoma of unknown primary site: treatment with one-hour paclitaxel, carboplatin and extended schedule etoposide. *J Clin Oncol* 1997;15:2385–2393.
145. Greco FA, Gray J, Burris HA, et al. Taxane-based chemotherapy with carcinoma of unknown primary site. *Cancer J* 2001;7:203–212.
146. Greco FA, Erland JB, Morrissey LH, et al. Phase II trials with docetaxel plus cisplatin or carboplatin. *Ann Oncol* 2000;11:211–215.
147. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with unknown primary site: a Minnie Pearl Cancer Research Network study. *J Clin Oncol* 2002;20:1651–1656.
148. Hainsworth JD, Burris HA, Calvert SW, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. *Cancer Invest* 2001;19:335–339.
149. Hainsworth JD, Spigel DR, Raefsky EL, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site. *Cancer* 2005;104:1992–1997.
150. Greco FA, Hainsworth JD, Yardley DA, et al. Sequential paclitaxel/carboplatin/etoposide followed by irinotecan/gemcitabine for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network phase II trial. *Oncologist* 2004;9:644–652.
151. Hainsworth JD, Spigel DR, Farley C, et al. Bevacizumab and erlotinib in the treatment of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. *J Clin Oncol* 2007;25:1747–1752.
152. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. *Cancer* 2010;116:2448–2454.
153. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. *Cancer J* 2010;16:70–75.
154. Dowell JE, Garrett AM, Shyr Y, et al. A randomized phase II trial in patients with carcinoma of an unknown primary site. *Cancer* 2001;91:592–597.
155. Pittman KB, Oliver IN, Koczwara R, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide cancer-trials and education collaborative study. *Br J Cancer* 2006;95:1309–1313.
156. Balana C, Manzano JL, Moreno L, et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavorable group of patients with carcinoma of unknown primary site. *Ann Oncol* 2003;14:1425–1429.
157. Piga A, Nortilli R, Cetto GL, et al. Carboplatin, doxorubicin and etoposide in the treatment of tumors of unknown primary site. *Br J Cancer* 2004;90:1898–1904.
158. Park YH, Ryou BY, Choi SJ, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavorable group of patients with cancer of unknown primary site. *Jpn J Clin Oncol* 2004;34:681–685.
159. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. *Cancer* 2004;100:1257–1261.
160. Briasoulis E, Fountzilas G, Bamias A, et al. Multicenter phase II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a Hellenic Cooperative Group study. *Cancer Chemother Pharmacol* 2008;62:277–284.
161. El-Rayes BF, Shields AF, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary site. *Am J Clin Oncol* 2005;28:152–156.
162. Palmeri S, Lorusso V, Palmeri L, et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinoma of unknown primary site. *Cancer* 2006;1007:2898–2905.
163. Schneider BJ, El-Reyes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site cancer. *Cancer* 2007;110:770–775.
164. Berry W, Elkordy M, O'Rourke M, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic? *Cancer Invest* 2007;25:27–31.
165. Hainsworth JD, Spigel DR, Thompson DS, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. *Oncologist* 2009;14:1189–1197.
166. Tan DSW, Montoya J, Ng DS, et al. Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. *J Clin Oncol* 2013;1:e273–239.
167. Penley WC, Spigel DR, Greco FA, et al. Confirmation of non-small cell lung cancer diagnosis using ALK testing and genetic profiling in patients presenting with carcinoma of unknown primary site. *J Clin Oncol* 2013;31:abstract e115004.
168. Gatalica Z, Millis S, Bender R, et al. Molecular profiling cancers of unknown primary: paradigm shift in management of CUP. Presented at: 2013 European Cancer Conference; September 30, 2013; Amsterdam.
169. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. *J Clin Oncol* 1994;12:1272–1280.
170. Lenzi R, Hess KR, Abbruzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary origin: favorable subsets of patients with unknown primary cancer? *J Clin Oncol* 1997;15:2056–2066.
171. van der Gaast A, Verweij J, Planting AST, et al. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. *J Clin Oncol* 1995;13:1720–1725.
172. Culine S, Kramar A, Saghatelyan M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinoma of unknown primary site. *J Clin Oncol* 2002;20:4679–4683.
173. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. *Cancer* 2006;107:2698–2705.
174. Wood LA, Venner PM, Pabst HF. Monozygotic twin brothers with primary immunodeficiency presenting with metastatic adenocarcinoma of unknown primary. *Acta Oncol* 1998;37:771–772.

175. Korbling M, Katz RL, Khanna A, et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral blood stem cells. *N Engl J Med* 2002;346:738–746.
176. McCulloch EA. Stem cells and diversity. *Leukemia* 2003;17:1042–1048.
177. Young HE, Duplax C, Romera-Ramos M, et al. Adult reserve stem cells and their potential for tissue engineering. *Cell Biochem Bio Phys* 2004;40:1–80.
178. Dieterien-Lievre F. [Lineage-switching by pluripotent cells derived from adults.] *J Soc Biol* 2001;195:39–46.
179. De Coppi P, Bartsch G, Siddiqui MM, et al. Isolation of amniotic stem cells with potential for therapy. *Nat Biotechnol* 2007;25:100–106.
180. Abbruzzese JL, Lenzi R, Raber MN, et al. The biology of unknown primary tumors. *Semin Oncol* 1993;20:238–243.
181. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. *Nat Genet* 2003;33:49–54.
182. Bar-Eli M, Abbruzzese JL, Lee-Jackson D, et al. P53 gene mutation spectrum in human unknown primary tumors. *Anticancer Res* 1993;13:1619–1623.
183. Briasoulis E, Tsakos M, Fountzilias G, et al. Be12 and p53 protein expression in metastatic carcinoma of unknown primary origin; biological and clinical implications. A Hellenic Cooperative Oncology Group study. *Anticancer Res* 1998;18:1907.
184. Pavlidis N, Briasoulis E, Baj M, et al. Overexpression of C-myc, Ras and C-erb-2 oncoproteins in carcinoma of unknown primary origin. *Anticancer Res* 1995;15:2563–2567.
185. Hainsworth JD, Lenington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. *J Clin Oncol* 2000;18:632–635.
186. Golfnopoulos V, Pentheroudakis G, Goussia A, et al. Intercellular signaling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary; a study of 100 cases. *Ann Oncol* 2012;23:2725–2730.
187. Stella GM, Benvenuti S, Gramaglia D, et al. MET mutations in cancers of unknown origin. *Hum Mutat* 2010; 32:44–50.
188. Koo JS, Kim H. Hypoxia-related protein expression and its clinicopathologic implication in carcinomas of unknown primary. *Tumour Biol* 2011;32:893–904.
189. Bonnefoi H, Smith IE. How should cancer presenting as a malignant pleural effusion be managed? *Br J Cancer* 1996;74:832–835.
190. Kuttesch JF, Parham DM, Kaste SC, et al. Embryonal malignancies of unknown primary origin in children. *Cancer* 1995;75:115–121.
191. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. *Clin Cancer Res* 2012;18:5773–5779.